1. Show article details.

    Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

    Business Wire – 8:00 AM ET 01/24/2022

    Horizon Therapeutics plc (HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 antagonist to treat people with IPF, the most common interstitial lung disease. IPF is a rare, progressive lung disease caused by inflammation and fibrosis, or scarring, of the lungs.

  2. Show article details.

    ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

    PR Newswire – 7:45 AM ET 01/11/2022

    LOS ANGELES, Jan. 11, 2022  ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer.

  3. Show article details.

    Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout

    Business Wire – 7:30 AM ET 01/10/2022

    -- Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients randomized to receive KRYSTEXXA plus methotrexate -- Horizon Therapeutics plc (HZNP) today announced that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration to expand the approved indication for KRYSTEXXA plus methotrexate, a...

  4. Show article details.

    Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability

    Business Wire – 8:00 AM ET 01/06/2022

    Horizon Therapeutics plc (HZNP) announced today that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the Alexandria Center® at Traville Gateway campus in Rockville, Maryland.

  5. Show article details.

    Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

    Business Wire – 8:00 AM ET 12/23/2021

    Horizon Therapeutics plc (HZNP) today announced that the Company will participate in the following upcoming virtual investor conferences: Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference: A View from the Top Tim Walbert, chairman, president and chief executive officer, will present at 9 a.m. ET on Thursday, Jan. 6, 2022.

  6. Show article details.

    BRIEF-Alpine Immune Sciences And Horizon Therapeutics PLC Announce Exclusive License And Collaboration DEAL

    Reuters – 9:41 AM ET 12/16/2021

    Horizon Therapeutics PLC (HZNP): * ALPINE IMMUNE SCIENCES AND HORIZON THERAPEUTICS PLC ANNOUNCE EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT TO DEVELOP NOVEL PROTEIN-BASED THERAPIES FOR AUTOIMMUNE AND INFLAMMATORY DISEASES Source text for Eikon: Further company coverage:

  7. Show article details.

    Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

    Business Wire – 8:00 AM ET 12/16/2021

    - Horizon will have exclusive rights to develop and commercialize up to four preclinical candidates – - Horizon will make a $40 million payment at closing, consisting of a $25 million upfront cash payment and a $15 million equity investment –. - Alpine eligible to receive additional payments of up to $381 million per program, or approximately $1.52 billion in total, related to success-based dev...

  8. Show article details.

    Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

    Business Wire – 8:00 AM ET 12/16/2021

    - Horizon will have exclusive rights to develop and commercialize up to four preclinical candidates - - Horizon will make a $40 million payment at closing, consisting of a $25 million upfront cash payment and a $15 million equity investment - - Alpine eligible to receive additional payments of up to $381 million per program, or approximately $1.52 billion in total, related to success-based deve...

  9. Show article details.

    Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater

    Business Wire – 9:00 AM ET 12/02/2021

    Horizon Therapeutics plc (HZNP) announced today it has made a $100,000 seed donation to promote community engagement around the renovation of Emmett Till’s childhood home in Chicago’s West Woodlawn neighborhood.

  10. Show article details.

    Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List

    Business Wire – 8:30 AM ET 12/02/2021

    Horizon Therapeutics plc (HZNP) announced today that it has been named to Great Place to Work’s 2021 Best Workplaces for Parents list, which highlights companies that have created consistently positive experiences for working parents.

  11. Show article details.

    Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education

    Business Wire – 1:30 AM ET 12/01/2021

    Horizon Therapeutics plc (HZNP) today announced $140,000 in scholarships to help economically disadvantaged students from Trinity College Dublin and Waterford Institute of Technology cover their non-tuition expenses.

  12. Show article details.

    New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Business Wire – 8:00 AM ET 11/22/2021

    -- Post hoc analysis of UPLIZNA Phase 2/3 trial shows all seven patients who had attacks while receiving rituximab were attack-free after switching to UPLIZNA -- Horizon Therapeutics plc (HZNP) today announced that a new post hoc analysis of the UPLIZNA N-MOmentum Phase 2/3 pivotal trial has been published in Multiple Sclerosis and Related Disorders showing that prior rituximab exposure did not impact...

  13. Show article details.

    Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative

    Business Wire – 9:00 AM ET 11/15/2021

    – Campaign helps people know their risks and identify the signs and symptoms of TED to encourage early diagnosis and management – Horizon Therapeutics plc (HZNP) today announced its support of Thyroid Eye Disease Awareness Week through the launch of new educational resources designed to help people IdentifEYE TED, with a focus on symptoms, risks and where to seek care.

  14. Show article details.

    New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)

    Business Wire – 8:33 AM ET 11/12/2021

    -- Analysis to be presented during AAO 2021 demonstrates 90% of patients finished full course of TEPEZZA therapy, indicating strong patient adherence -- Horizon Therapeutics plc (HZNP) today announced findings of a real-world adherence analysis of TEPEZZA for the treatment of TED at the American Academy of Ophthalmology Annual Meeting.

  15. Show article details.

    Horizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Business Wire – 7:29 AM ET 11/12/2021

    -- CHMP recommendation based on positive results from N-MOmentum, the largest clinical trial ever conducted in NMOSD to date -- -- In the trial, UPLIZNA was shown to reduce the risk of relapse by 77% compared to placebo in anti-aquaporin-4 antibody positive adult patients -- -- Treatment is given via infusion every six months following an initial two treatments spaced two weeks apart -- -- UPLI...

  16. Show article details.

    Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

    Business Wire – 8:00 AM ET 11/09/2021

    Horizon Therapeutics plc (HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 antagonist to treat people with diffuse cutaneous systemic sclerosis, a subset of systemic sclerosis.

  17. Show article details.

    Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

    Business Wire – 4:05 PM ET 11/08/2021

    Horizon Therapeutics plc (HZNP) today announced that the Company will participate in the following upcoming conferences: Guggenheim 3rd Annual Neuro/Immunology Conference Stifel 2021 Health Care Conference Piper Sandler 33rd Annual Health Care Conference These conference presentations will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay ...

  18. Show article details.

    Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco

    Business Wire – 9:01 AM ET 11/05/2021

    Horizon Therapeutics plc (HZNP) today announced that it has been named one of the Chicago Tribune’s Top Workplaces 2021, ranking No. 5 out of 75 other midsize companies in the Chicago area. “We are always honored to be named to the Chicago Tribune’s Top Workplaces list,” said Tim Walbert, chairman, president and chief executive officer, Horizon.

  19. Show article details.

    Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week

    Business Wire – 1:00 PM ET 11/04/2021

    -- Complete data from PROTECT trial shows 89% of patients achieved the primary endpoint -- -- Additional presentations call attention to the high prevalence of gout and its associated comorbidities among individuals undergoing dialysis -- DUBLIN---- Horizon Therapeutics plc (HZNP) today announced the presentation of results from the completed PROTECT trial evaluating KRYSTEXXA® in people with chronic ...

  20. Show article details.

    BRIEF-Horizon Therapeutics PLC Announces Chief Financial Officer Succession Plan

    Reuters – 8:33 AM ET 11/03/2021

    Horizon Therapeutics PLC (HZNP): * HORIZON THERAPEUTICS PLC ANNOUNCES CHIEF FINANCIAL OFFICER SUCCESSION PLAN. * Horizon Therapeutics PLC (HZNP) - PAUL HOELSCHER, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER, WILL RETIRE EFFECTIVE MAY 16. * Horizon Therapeutics PLC (HZNP) - AARON COX, WHO WAS NAMED EXECUTIVE VICE PRESIDENT, FINANCE, WILL SUCCEED HOELSCHER Source text for Eikon: Further company coverage:

Page:

Today's and Upcoming Events

  • Feb
    23

    HZNP to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    03

    HZNP announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.